Previous 10 | Next 10 |
P RESS RELEASE Immunocore announces the presentation of initial data from the P hase 1 ImmTAV ® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC- I109V , T cell recep...
Immunocore (NASDAQ:IMCR) said on Friday that Ocumel Canada and Save Your Skin Foundation applauded Canada's approval of Kimmtrak to treat a type of rare cancer called uveal melanoma. Uveal melanoma is a type of cancer that begins in the cells that make the dark-colored pigment, called melanin...
The following slide deck was published by Immunocore Holdings plc in conjunction with this event. For further details see: Immunocore Holdings (IMCR) Investor Presentation - Slideshow
Immunocore Appoints Sidd h art h Kaul to its Board of Directors (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commer...
The U.K. Medicines and Healthcare products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada granted marketing authorization to Immunocore's (NASDAQ:IMCR) Kimmtrak to treat HLA-A 02:01-positive adult patients with unresectable or metastatic uveal mela...
The UK Medicine s and Healthcare products Regulatory Agency ( MHRA ) , Australian Therapeutic Goods Administration (TGA) and Health Canada a pprove KIMMTRAK® ( tebentafusp ) for the treatment of unresectable or metastatic uveal ...
P RESS RELEASE Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Tebentafusp and anti-PDL1 show 1 ye...
Commercial-stage biotech Immunocore Holdings (NASDAQ:IMCR) announced Friday that Sanofi (SNY) (OTCPK:SNYNF) has entered into a clinical trial collaboration and supply agreement with the company to target certain patients with advanced skin cancers. Per the terms, Sanofi (SNY) will assess its ...
Immunocore announce s c linical t rial c ollaboration with Sanofi to evaluate Sanofi’s product candidate SAR 444 245 , non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous me...
P RESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Updated overall survival (OS) data from Ph ase 1b metastatic cutaneous melanoma trial O ral pr...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore Holdings plc Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F10...